Compare ConocoPhillips (COP) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ConocoPhillips vs Summit Therapeutics Inc — how do they compare? ConocoPhillips trades at $134.66 (market cap $161.21B), while Summit Therapeutics Inc trades at $17.4 (market cap $13.71B). The key difference: ConocoPhillips is far larger — about 11.8× Summit Therapeutics Inc's market cap, and ConocoPhillips pays a 2.5% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold ConocoPhillips for 79 Days and Summit Therapeutics Inc for 16 Days on average.
| COP | SMMT | |
|---|---|---|
Market Cap | $161.21B | $13.71B |
Volume | 6,058,403 | 6,173,057 |
Sector | Energy | Health |
52-Week High | $141.22 | $26.38 |
52-Week Low | $85.66 | $12.43 |
Typical Hold Time | 79 Days | 16 Days |
Enterprise Value | $176.81B | $13.04B |
Dividend Yield | 2.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ConocoPhillips (COP) trades at $134.52, up 3.6% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with Q2 2026 EPS beating expectations at $3.24 versus $2.90, supported by a 20-year LNG supply agreement with Venture Global. Valuation metrics appear reasonable with P/E at 17.75 and EV/EBITDA at 6.36, while profitability remains solid with 14.65% net income margin and 14.14% ROE.
Outlook remains positive with consensus price target of $154.75 representing 15% upside potential. Key risks include oil price volatility and geopolitical exposure in international operations. The company's strong cash flow generation and strategic LNG expansion provide growth catalysts, though investors should monitor execution on asset sales and energy market dynamics.
Summit Therapeutics (SMMT) trades at $17.29, down 3.68% on the day, amid a bullish technical signal driven by moving averages. The company reported no revenue and a net loss of $1.08 billion in 2025, with negative profitability ratios, but recent news of a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations has boosted investor optimism.
The outlook is speculative, with significant upside potential based on the $29.33 analyst consensus price target, but high execution risk remains as the company is pre-revenue and reliant on clinical trial success. Key catalysts include upcoming trial results for ivonescimab, while risks involve drug development setbacks and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ConocoPhillips
ConocoPhillips is a U.S.-based independent exploration and production firm. In 2021, it produced 1.0 million barrels per day of oil and natural gas liquids and 3.2 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2021 were 6.1 billion barrels of oil equivalent.
Read more on COP →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
